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Background & Objective. Ultrarush induction for specific venom immunotherapy has been shown to be reliable and eﬃcacious
in adults. In this study its safety and tolerance in children was evaluated. Methods. Retrospective analysis of 102 ultrarush
desensitizations carried out between 1997 and 2005 in 94 children, aged 4 to 15 years. Diagnosis and selection for immunotherapy
were according to recommendations of the European Academy of Allergy and Clinical Immunology. Systemic adverse reactions
(SARs) were described using the classification of H. L. Mueller. Results. All patients reached the cumulative dose of 111.1 µg
hymenoptera venom within 210 minutes. Six patients (6%) had allergic reactions grade I; 2 patients (2%) grade II and 5 patients
(5%) grade III. Three patients (3%) showed unclassified reactions. SARs did not occur in the 15 patients aged 4 to 8 years and they
were significantly more frequent in girls (29%) compared with boys (12%) (P = 0.034, multivariant analysis) and in bee venom
extract treated patients (20%) compared to those treated with wasp venom extract (8%) (OR 0.33, 95% Cl 0.07–1.25). Conclusion.
Initiation of specific immunotherapy by ultrarush regimen is safe and well tolerated in children and should be considered for
treating children with allergy to hymenoptera venom.
1. Introduction
Hypersensitivity to hymenoptera venom aﬀects approxi-
mately 1%–5% of the general population. In Switzerland the
prevalence is estimated to be 3.5% in the general population
and 0.4%–0.8% in children aged 4 to 16 years. It is one of the
three most common causes of immediate type anaphylactic
reactions, the other two major causes being drugs and foods
[1]. A field sting in a hymenoptera venom allergic patient
can cause a spectrum of reactions ranging from severe local
swelling to anaphylactic shock with circulatory collapse. Sev-
eral cases of death are attributed to hymenoptera allergy
yearly, mostly in adults.
Specific immunotherapy (SIT) is the only known causal
treatment for venom-allergic patients [2, 3]. In subjects with
a history of generalized reactions to insect sting SIT results
in up to 95% rate of protection in wasp venom allergic
patients and 80% in bee venom allergic patients [4]. Diﬀerent
protocols have been published for the stepwise increase of the
dose of the insect venom during initiation of subcutaneous
specific immunotherapy [5–9]: the conventional regime,
with injections using increasing doses every one to two weeks
over a period of 2 to 4 months, rush immunotherapy extend-
ing over approximately 1 week and ultrarush protocols, in
which the maintenance dose is achieved in 1-2 days. The
latter has been shown to be eﬀective and time-saving in
adults [5]. The aim of this retrospective study was to
investigate the safety and tolerance of ultrarush induction in
desensitization in children.
A systemic grading of reactions to immunotherapy is
necessary in order to evaluate the safety of the treatment
and in order to compare various regimens [10]. In this study
we chose to use a modified version of the classification of
generalized allergic reactions introduced by H. L. Mueller in
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Figure 1: Ultrarush induction regimen in desensitization with subcutaneous venom injections.
1966 [11]. This classification is presented in Table 2 for quick
reference.
2. Methods
2.1. Patients. Medical records of 94 children treated with the
ultrarush induction regime in the intensive care unit of the
University Children’s Hospital of Zurich between January
1997 and December 2005 were analysed retrospectively; the
clinical data is summarized in Table 1. Indication for SIT was
a combination of an immediate systemic allergic reaction
grade III or IV after a hymenoptera field sting and detection
of specific IgE antibodies to the venom, as recommended
by the European Academy of Allergy and Immunology Sub-
committee on insect venom allergy [4, 6]. Patients with less
severe reactions were included when the risk of exposure was
very high, for example, when a wasp nest was in close prox-
imity to the home, or when the fear from getting a sting
caused anxiety and a significant limitation in the quality of
life.
The study population included 24 girls and 70 boys; 61 of
the patients were allergic to bee venom, 33 to wasp-venom;
and 8 boys to both. These 8 boys were considered twice in
the evaluation. The patients were divided into three groups
according to age: group A included 15 patients aged 4 to 8
years, in group B there were 60 subjects aged 8 to 12 years and
in group C 27 patients aged 12 to 15 years. The classification
of generalized allergic reactions according to H. L. Mueller
which was used to define the adverse reactions is shown in
Table 2.
2.2. Tests. Sensitization was detected by skin prick tests with
10, 100, and 300 µg/mL purified insect venom extract (Phar-
malgen, ALK) and/or intradermal tests with 0.00001, 0.001,
0.01, 0.1, and 1.0 µg/mL purified venom extract (ALK-SQ,
ALK-Scherax, Germany). The tests were considered positive
if a weal of at least 3mm in diameter occurred after 15
minutes, and, in the case of intradermal tests, a reaction was
considered positive at a concentration of 1 µg/mL or less.
Positive (1% histamine hydrochloride) and negative (sodi-
um-chloride 0.9%) control tests were performed. In addition
levels of specific IgE were determined in serum (Pharmacia
ImmunoCAP System, Sweden); they were considered nega-
tive when less than 0.35 kU/L.
2.3. Induction of Specific Immunotherapy Using the Ultrarush
Regime. The ultrarush induction regime is described in
Figure 1. All patients were treated with a standardized pu-
rified venom preparation (ALK Pharmalgen, Trimedal) given
in subcutaneous injections. The cumulative dose of 111.1 µg
hymenoptera venom was reached after 210 minutes using at
least 6 injections. In the case of side eﬀects, the interval
between the doses was extended. The patients were observed
in the intensive care unit with intravenous access, continu-
ous measurements of the oxygen saturation, and repeated
measurements of the blood pressure. Three hours after the
last injection the patients were discharged to home. Booster
injections were given later as follows: on day 7 two doses
of 50 µg (ALK Pharmalgen, Trimedal) were given with an
interval of 30 minutes, and 3 and 7 weeks after the ultrar-
ush procedure the patients received 100 µg of Alutard
(Aluminiumhydroxid-depot-preparation, ALK) subcutane-
ously. During the entire therapy the children did not receive
premedication with antihistamines.
If both wasp and bee venoms sensitizations were re-
quired; they were administered in separate protocols a few
days apart.
3. Results
Between January 1997 and December 2005 94 children, aged
4 to 15.1 years, including 70males and 24 females, underwent
induction of specific immunotherapy using ultrarush regime
in the intensive or intermediate care unit of the University
Children’s Hospital of Zurich. A total of 102 ultrarush
immunotherapy induction procedures were performed, in
all of which the cumulative dose of 111.1 µg was reached.
61 patients were treated with bee venom, 33 with wasp ven-
om, and 8 boys with both. Average duration of the procedure
was 3.5 hours with a range of 2.5 to 5.5 hours.
3.1. Adverse Reactions. All patients had local swelling and
redness of the upper arm with a diameter of less than
10 cm. As summarized in Table 3, Systemic side eﬀects were
observed in 16 subjects (16%), 11 of them required treat-
ment. 6 patients (6%) showed an allergic reaction grade I,
2 girls (2%) grade II, and 5 patients (5%) developed a grade
III reaction, 1 of these 5 subjects recovered spontaneously.
No grade IV reactions occurred. 3 (3%) patients showed a
reaction which could not be classified according to Mueller,
namely, prickle of the tongue and throat and dizziness.
Severe adverse reactions occurred mainly after injection of
50 µg venom (9 subjects) and more often in bee venom (13
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Table 1: Clinical data of children undergoing ultrarush venom immunotherapy.
No. patients Total 94 Bee venom ultrarush Wasp venom ultrarush
Age in years
Range 4.0–15.1
Mean, median 10.4, 10.5
Gender
Boys 78 (76.5 %) 47 (46.1%) 31 (30.4%)
Girls 24 (23.5 %) 18 (17.6%) 6 (5.9%)
Allergen
Bee venom 57 (55.9 %) 65 (63.7%)
Wasp venom 29 (28.4 %) 37 (36.3 %)
Both 8 (7.8 %)
Grade of reaction to field sting
I 1 (1.0%) 1 0
II 20 (19.6%) 13 7
III 60 (58.8%) 37 23
IV 15 (14.7%) 9 6
Other (Sensitisation) 6 (5.9%) 5 1
Table 2: Classification of allergic reactions after HL Mueller, modified.
Reaction
Large local reaction Swelling at site of sting with diameter >10 cm, lasting >24 h
Grade I Generalized urticaria, itching, malaise, anxiety
Grade II
Any of the above, plus two or more of the following: angiooedema (grade II also if alone), constriction in
chest, nausea, vomiting, diarrhoea, abdominal pain, dizziness
Grade III
Any of the above, plus two or more of the following: dyspnoea, wheezing, stridor (any of these alone are
grade III), dysphagia, dysarthria, hoarseness, weakness, confusion, fear of death
Grade IV
Any of the above, plus two or more of the following: drop of blood pressure, collapse, loss of
consciousness, incontinence (urine, stool), cyanosis
patients, 20%) than in wasp venom (3 patients, 8%) al-
lergic subjects; this latter tendency however, was not statis-
tically significant (OR 0.33, 95% Cl 0.07–1.25, P = 0.0955).
Overall, 29% of the girls, compared to only 12% of the
boys, developed a systemic adverse event; this diﬀerence was
statistically significant (P = 0.034, multivariant analysis).
None of the patients in group A (4 to 8 years of age) showed
systemic side eﬀects compared to 18% in group B (8 to
12 years of age) and 19% in group C (12 to 15 years of
age). All but one reaction occurred within 30 minutes after
injection of venom. In one boy generalised urticaria devel-
oped 3 hours after injection.
4. Discussion
When starting specific immunotherapy, various protocols
for increasing the dose of allergen up to the maintenance
dose have been introduced in the past years, attempting to
maximize protection, minimize side eﬀects, and optimize
patient convenience. It is diﬃcult to compare the results
because the regimens diﬀer. Increasing data in adults demon-
strate good tolerance and safety for the ultrarush induction
in insect venom immunotherapy. For example, Birnbaum
et al. found fewer systemic reactions with a 3.5-hour
(210min) protocol with a cumulative dose of 101.1 µg venom
compared to 6-hour and to 4-day protocols, which attained
cumulative doses of 226.6 µg and 527.6 µg, respectively [5,
7]. The nine years of experience with initiation of specific
immunotherapy to insect venom by ultrarush protocol in
paediatric subjects, which is summarized in this paper,
demonstrates that ultrarush insect venom immunotherapy is
a well-tolerated and safe induction regimen also in children.
Few side eﬀects were observed, no cardiac or circulatory side
eﬀects and no systemic allergic reactions in the youngest age
group (4–8 years). Three subjects had unclassified reactions
with prickle of the tongue and throat and dizziness. These
reactions did not fit the usual categories of allergic reactions,
and it was not clear whether they were related directly
to the immunotherapy or whether they were caused by
the circumstances of the treatment (hospitalization in the
intensive/intermediate care unit, subcutaneous injections,
monitoring, etc.). In order to assess this question a control
group undergoing the same procedures but getting placebo
injections would be needed. However, this was beyond the
scope of this retrospective study.
Antihistamines are eﬃciently andwidely used to suppress
allergic symptoms. There are studies which support the
strategy of premedication with antihistamines in order to
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Table 3: Subjects with side eﬀects.
Sex Age (y) Insect Grade at sting Side eﬀects Grade At dose in µg Therapy
F 8.1 Bee II
Generalized urticaria,
cough (no wheezing,
no dyspnoea, no
stridor)
II 50
Antihistamines,
Corticosteroids i.v.
M 9.5 Bee Sensit. (IV) Dizziness other 30 None
M 9.5 Bee II-III Generalyzed urticaria I 30 Antihistamines i.v.
M 10.9 Bee III
Urticaria, dyspnoea,
wheezing
III 30
Antihistamines,
Corticosteroids i.v.,
Salbutamol-inhalation
M 14.7 Bee III
Generalized urticaria;
dyspnoea, constriction
in chest
IIII 2050
Antihistamines,
Corticosteroids i.v.dito +
inhal. of
Adrenalin/Salbutamol
F 10.3 Bee II-III
Urticaria about 3 h
after last injection
(50 µg)
I 50
Antihistamines,
Corticosteroids i.v.
F 10.4 Bee II
Slight dyspnoea; fast,
spontaneous
normalization
III 1 None
M 12.1 Bee III-IV
Generalized urticaria,
itching in the throat
I 30
Antihistamines,
Corticosteroids i.v
M 10.5 Bee II-III Itching in the throat other 50 Cetirizin per os
F 8.7 Bee III
Chest pain, inspiratory
stridor, chest pain,
in-and expiratory
stridor
IIIIII 1050
Antihistamines,
Corticosteroids i.v.,
Adrenalin-inhalation dito +
Salbutamol-inhalation,
Corticosteroids i.v. (before
going home)
F 14.1 Bee III
Slight periorbital
swelling
II 1, 30 and 50
Antihistamines i.v. after
1ug
M 15.1 Bee II
Itching in meatus
acusticus, rash chest,
several urticarial
lesions on the left arm
I 50 None
F 15.0 Wasp III
Dysphagia, passing
dyspnea
III 0.1
Antihistamines and
Corticosteroids i.v, and
again before going home
F 11.3 Wasp III
Slight prickle of the
tongue
other 10 None
M 10.3 Bee IV
Redness and one
urticarial lesion on the
left cheek
I 50
none, 1 Levocetirizine per
os before going home
M 10.7 Wasp III Generalyzed urticaria I 50 Levocetirizin per os
All children
Local redness and swelling, sometimes overheating and itching at the injection site.
Therapy if needed: Coldpack and/or Antihistamin gel
reduce allergic side eﬀects and enhance the safety and eﬃcacy
of allergen-specific immunotherapy [12, 13]. However, there
is also data which suggests that medication with antihis-
tamines may impair allergen-specific immunotherapy [14].
The patients in this retrospective study did not receive treat-
ment with antihistamines prior to immunotherapy.
The results presented in this paper compare favourably
with the frequency of side eﬀects reported in adults and
with the incidence of severe adverse reactions in conventional
and rush protocols [5, 7, 15–20]. The ultrarush induction
protocol performed in a paediatric intensive or intermediate
care unit allows for much better monitoring of the patients
compared to the conventional desensitization protocol per-
formed in an outpatient setting. Its short duration is much
more convenient for the patients and their parents, and it
has the additional advantages of achieving rapid protection
as well as reduction in costs. Based on the results presented
in this paper and due to these considerations, we suggest
that the ultrarush induction regimen for desensitization,
when performed in a suitable intensive care setting, will be
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considered the treatment of choice in paediatric patients with
hymenoptera venom allergy who qualify for immunother-
apy.
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